3
Clinical Trials associated with CPL2009-0031Prospective, Randomized, Double Blind, Parallel Group, Two Arm, Comparative, Multicenter, Clinical Study to Compare Efficacy and Safety of Oral CPL-2009-0031 140 mg of Cadila Pharmaceutical Limited, India Against Innovator Sitagliptin 100 mg in Patients With Uncontrolled Type-2 Diabetes Mellitus (T2DM)
This trial is a Phase-III, Prospective, Randomized, Double Blind, Parallel Group, Two arm, Comparative, Multicenter, controlled clinical trial to determine the efficacy, safety, and tolerability of oral CPL-2009-0031 140 mg in comparison with Sitagliptin 100 mg in patients with Uncontrolled Type-2 Diabetes Mellitus (T2DM).
Prospective, Randomized, Double Blinded, Parallel Group, Multicentric, ComparativeClinical study to compare efficacy and safety of oral CPL-2009-0031 of CadilaPharmaceutical Limited, India against innovator Sitagliptin in patients with UncontrolledType-2 Diabetes Mellitus (T2DM). - CPL-2009-0031
A safety, pharmacokinetics and pharmacodynamics study of CPL-2009-0031 in healthy volunteers and patients with Type 2 Diabetes mellitus (T2DM).
100 Clinical Results associated with CPL2009-0031
100 Translational Medicine associated with CPL2009-0031
100 Patents (Medical) associated with CPL2009-0031
100 Deals associated with CPL2009-0031